recombinant somatropin
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infant, Small for Gestational Age
Conditions
Infant, Small for Gestational Age
Trial Timeline
Mar 1, 2009 → Dec 1, 2015
NCT ID
NCT01082354About recombinant somatropin
recombinant somatropin is a pre-clinical stage product being developed by Merck for Infant, Small for Gestational Age. The current trial status is completed. This product is registered under clinical trial identifier NCT01082354. Target conditions include Infant, Small for Gestational Age.
What happened to similar drugs?
4 of 14 similar drugs in Infant, Small for Gestational Age were approved
Approved (4) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01082354 | Pre-clinical | Completed |
Competing Products
20 competing products in Infant, Small for Gestational Age
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SPIKEVAX | Moderna | Preclinical | 0 |
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 30 |
| somatropin | Eli Lilly | Phase 3 | 40 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 35 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 40 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 32 |
| MAS825 + Placebo | Novartis | Phase 2 | 39 |
| epoetin beta + epoetin beta | Roche | Pre-clinical | 26 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 40 |
| Prevenar (13v) | Pfizer | Pre-clinical | 26 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 35 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 35 |
| DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV | Sanofi | Phase 3 | 40 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 43 |
| Radiprodil | UCB | Phase 2 | 27 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 23 |
| Sabril® | Lundbeck | Pre-clinical | 23 |
| Vigabatrin | Lundbeck | Approved | 32 |